西地尼布在卵巢癌中的研究进展

Progress of Cediranib in the Treatment of Ovarian Cancer

卵巢癌是妇科常见的恶性肿瘤之一,其预后较差:大多数确诊患有卵巢癌的患者最终会因为该疾病而死亡。在近年来进行的多项临床试验中,常规化疗药物的新联合方案均未能显著改善卵巢癌患者的预后。现在我们已经进入"个体化用药"时代:新的药物可特异性靶向作用于涉及癌变和进展的分子通路。在这种背景下,最为成功的靶向分子途径是肿瘤血管生成。西地尼布(Cediranib)是靶向作用于血管内皮生长因子受体(Vascular endothelial growth factor receptor,VEGFR)的酪氨酸激酶抑制剂,在多项试验中均取得了令人满意的结果。本综述旨在回顾西地尼布在卵巢癌中的作用。

Ovarian cancer is one of common gynecologic malignancies, and its prognosis is poor: most patients diagnosed with this disease willultimately die from it. In various clinical trials conducted recently, new combinations of conventional chemotherapy regimens have failed to achievesignificant improvements in prognosis for ovarian cancer patients. Now, we have entered an era of “personalized medicine” and new medicationsare designed to specifically target molecular pathways involved in carcinogenesis and cancer progression. One of the most successfully targetedmolecular pathways is tumor angiogenesis. Cediranib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR).It has been tested in various trials and all achieved promising results. The aim of this review is to summarize the role of cediranib in the treatment ofovarian cancer.